| “The Future of Oncology Therapeutics - | | | | regulations, the market is expected to slow down |
| Market Forecasts to 2015, Competitive | | | | to 11% between 2008 and 2015 and record sales |
| Benchmarking, Product Pipeline and Deals | | | | value of $55.1 billion by 2015. Similarly, in 2008, the |
| Analysis”, this report is an essential source of | | | | oncology therapeutics market in the EU5 countries |
| data and analysis on the cancer market in the top | | | | was estimated at approximately $15.5 billion, |
| 7 markets of the world. It covers the market | | | | indicating a CAGR of 15.7% between 2000 and |
| landscape, key market trends, market drivers and | | | | 2008. Oncology therapeutics market in Japan was |
| restraints. The report also identifies key | | | | estimated at approximately $6.1 billion, indicating a |
| treatment usage patterns across 7 major | | | | CAGR of 15.6% between 2000 and 2008. |
| markets namely, the US, EU5 and Japan. In | | | | Breast Cancer Therapeutic Indication was the |
| addition, it brings out the existing competitive | | | | Leading Therapy Market with an Estimated |
| landscape of the oncology therapeutics market, | | | | Market Share of 16% of the Global Oncology |
| characteristics of the top five market indicators, | | | | Therapeutics Market |
| and mergers and acquisitions that have taken | | | | In 2008, the top five cancer therapeutic |
| place involving cancer therapies over the last one | | | | indications accounted for approximately 58.1% of |
| year. ( ) | | | | the global oncology therapeutics market. Breast |
| The Global Oncology Therapeutics Market is | | | | cancer was the leading therapeutic indication with |
| Forecast to Grow at More Than the Overall | | | | an estimated market share of 16.5%, followed by |
| Pharmaceutical Industry Growth Rate | | | | Non-Hodgkin’s lymphoma (NHL) and colorectal |
| The global oncology therapeutics market was | | | | cancer (CRC) which accounted for an |
| valued at $48.1 billion in 2008. The growth in the | | | | approximate market share of 12.8% and 11.4%, |
| market is primarily driven by the rapid uptake of | | | | respectively. Prostate cancer therapeutics market, |
| target therapies and new developments that have | | | | with an estimated market share of 10.5%, was |
| come to treat the niche segments such as renal | | | | the next leading therapeutic indicator, followed by |
| cell carcinoma, liver cancer and stomach cancers | | | | lung cancer. |
| with high unmet needs. However, the growth of | | | | Roche/Genentech, Novartis and Sanofi-Aventis |
| the market is expected to slow down marginally | | | | are the Top Three Players Operating in the Global |
| due to the influx of many “me too” | | | | Oncology Market |
| versions of established therapies. In spite of this, | | | | In 2008, the top ten companies in the oncology |
| the global cancer therapeutics market is expected | | | | therapeutics market accounted for 82.3% of the |
| to grow at a Compound Annual Growth Rate | | | | global oncology therapeutics market. Rituxan was |
| (CAGR) of 10.9% between 2008 and 2015. | | | | the leading cancer therapy brand with an |
| The US, with an Approximate Market Share of | | | | approximate sales value of $5.5 billion, followed by |
| 55.1% in 2008, was the Leading Market in the | | | | Avastin, which recorded sales of $4.8 billion and |
| Global Cancer Therapeutics market | | | | Herceptin, which registered net sales worth $4.7 |
| In 2008, the oncology therapeutics market in the | | | | billion. The top three companies namely, Roche |
| US was estimated at approximately $26.5 billion, | | | | Genentech, Novartis and Sanofi-Aventis, |
| indicating a CAGR of 16.3% between 2000 and | | | | accounted for approximately 50% of the global |
| 2008. However, in anticipation of new healthcare | | | | oncology therapeutics market in 2008. |